🔎 Trials Near Me

홈 › 급성 골수성 백혈병 › 메릴랜드

메릴랜드의 급성 골수성 백혈병 임상 시험

급성 골수성 백혈병 관련 연구 31개가 메릴랜드 내 여러 지역에서 참여자를 모집하고 있습니다.

메릴랜드의 도시

공식 연구 텍스트(영어)

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1상
18세 ~ 120세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06904066

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
  • 외 10개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Walter Reed National Military Medical Center, Bethesda
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Center for Cancer and Blood Disorders, Bethesda
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05564390

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
피험자 모집 중초기 1상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06398457

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Walter Reed National Military Medical Center, Bethesda
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT05554406

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

  • Johns Hopkins University, Baltimore
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06284486

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • 외 1개
피험자 모집 중3상
6 Months – 21 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • John Hopkins School of Medicine, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT06824168

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1/2상건강한 지원자 환영
12세 ~ 120세 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT05436418

Longitudinal Studies of Patient With FPDMM

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구건강한 지원자 환영
1 Day – 100 Years · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT03854318

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • The Center for Cancer and Blood Disorders, Bethesda
피험자 모집 중관찰 연구
0세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Baltimore MD-UMGCCC, Baltimore
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Baltimore MD-UMGCCC, Baltimore
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • University of Maryland/Greenebaum Cancer Center, Baltimore
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

  • Tania Jain, MD, Baltimore
피험자 모집 중1상
6 Months – 80 Years · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT02203903

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구건강한 지원자 환영
18세 ~ 120세 · 모든 성별 · 2026. 7. 23. 업데이트됨 · NCT05588154

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구건강한 지원자 환영
1 Day – 120 Years · 모든 성별 · 2026. 7. 23. 업데이트됨 · NCT05350748

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • University of Maryland Medical Center (UMMC), Baltimore
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 7. 17. 업데이트됨 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Johns Hopkins, Baltimore
  • Nih/Niaid, Bethesda
  • Nih/Nhlbi, Bethesda
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구
1 Month – 120 Years · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT07019155

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 1. 업데이트됨 · NCT04050280

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  • The Center for Cancer and Blood Disorders (CCBD), Bethesda
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 24. 업데이트됨 · NCT04068597

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Sibley Memorial Hospital, Baltimore
  • University of Maryland, Baltimore
  • Johns Hopkins Main Center, Baltimore
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Johns Hopkins School of Medicine, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Johns Hopkins University, Baltimore
피험자 모집 중건강한 지원자 환영
18세 ~ 120세 · 모든 성별 · 2025. 7. 25. 업데이트됨 · NCT05237258

ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.